• Drug Companies Withdraw PARPi Indications for Ovarian Cancer

    6 days ago - By Medscape

    Zejula, Lynparza, and Rubraca have been voluntarily withdrawn for late-line ovarian cancer treatment indications over concerns surrounding an increased risk for death.
    Medscape Medical News
    Read more ...